MTOR and neoplasm: More importantly, exogenously added PTEN-Long to HepG2 cells resulted in reduced p-AKT, p-PRAS40, and p-mTOR, which inhibited tumor cell proliferation and migration without any significant change induced in HepG2 cells after treatment with exogenous PTEN protein.